Healthcare / Medical DevicesParis
$22.00
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $13.4M · quality 70.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$222M
P/E
46.8x
↑EV/EBITDA
8.3x
↓ROE
2.6%
↑Gross Margin
45.6%
↓Debt/Equity
0.09
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+3.4%
FCF CAGR
-46.2%
FCF margin
3.7%
FCF / Net income
1.29x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $168.6M · net income $4.9M · FCF $6.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $168.6M | $168.6M | $154.6M | $130.0M | $152.6M |
| Net Income | $4.9M | $4.9M | $4.0M | $4.8M | $24.9M |
| EBITDA | $26.7M | $26.7M | $27.5M | $25.6M | $40.2M |
| EPS | 0.47 | 0.47 | 0.39 | 0.43 | 2.20 |
| Gross Margin | 45.6% | 45.6% | 46.3% | 43.7% | 46.5% |
| Operating Margin | 6.4% | 6.4% | 6.3% | 7.8% | 20.2% |
| Net Margin | 2.9% | 2.9% | 2.6% | 3.7% | 16.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.09 | 0.09 | 0.19 | 0.58 | 0.66 |
| Current Ratio | 2.63 | 2.63 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $6.3M | $6.3M | $13.4M | $22.7M | $40.2M |
| Returns | |||||
| ROE | 2.6% | 2.6% | 2.2% | 2.8% | 14.4% |
| Valuation | |||||
| P/E | 46.81 | 46.81 | 64.87 | 37.67 | 8.94 |
| EV/EBITDA | 8.29 | 8.29 | 9.89 | 9.14 | 7.23 |
| P/B | 1.23 | 1.23 | 1.45 | 1.04 | 1.29 |
| Growth & Yield | |||||
| Revenue Growth | 9.1% | 9.1% | 18.9% | -14.8% | — |
| EPS Growth | 20.5% | 20.5% | -9.3% | -80.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
60.7%
EPS terminal req.
$1.95
Spread vs growth
-40.2%
5Y implied EPS CAGR
38.1%
EPS terminal req.
$2.36
Spread vs growth
-17.6%
10Y implied EPS CAGR
23.3%
EPS terminal req.
$3.80
Spread vs growth
-2.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-12.9%
Start / end P/E
64.7x → 46.8x
EPS bridge
0.39 → 0.47
Residual
-5.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.